Treatment
Chemotherapy for craniopharyngiomas is a consideration, particularly in young patients with a single cyst and small solid component. It is administered via ommaya reservoir, ensuring no previous leakage.
- Intracystic bleomycin: 2–5 mg 3 times/week, up to 12 doses in a course (23). Usually, each patient received only one course; however, some had a repeat course at time of recurrence.
- Intracystic interferon alpha-2b: 3 million IU 3 times/week for a total of 12 doses (4, 6).
- Intracystic chemotherapy only temporizes: Most patients require more definitive therapy later; the use of radiotherapy has been delayed successfully by several years in some cases (22).
Adjuvant Therapy
- Radiation: Involved field, stereotactic or proton beam, if possible, have been used to manage craniopharyngiomas.
Complications
- Bleomycin: Peritumoral edema leading to deterioration in level of consciousness, infarction, pituitary dysfunction, deterioration in vision, hypothalamic dysfunction requiring supportive care, and two toxic deaths have been reported (23).
- Interferon: Fatigue, arthritis, headache, and depression have all been reported (6). These complications were managed with symptomatic therapy.
Outcome
- Bleomycin: The median PFS was 1.8 years (0.3–6.1 years). In 11/17 patients a sustained benefit was observed for >1year; the median delay for need of an additional therapy in this group was 3.6 years (1.6–9.3 years) (23).
- Interferon: Disease control was achieved in 78% of 60 patients treated. 81% of 37 patients evaluated had a cyst reduction of greater than 50% (4)
Please create a free account or log in to read 'Chemotherapy for Craniopharyngiomas in Children'
The ISPN Guide and ISPN Library are one platform. Register once and complete your profile to access both resources.
